GlassScriptPhysician profile
Chey Herman
NPI 1811514839
$5,938.02
in general payments reported to CMS, 2019-2025
24 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,427 · 2022: $880 · 2023: $1,157 · 2024: $1,007 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,619.43 | 2021-2025 | |
| Novo Nordisk INC | $1,186.41 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $688.75 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $398.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $342.72 | 2021-2025 | |
| Stryker Corporation | $334.85 | 2021-2023 | Mako |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.15 | 2021-2025 | Jardiance |
| Amgen INC. | $187.12 | 2023-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $171.77 | 2023-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $165.76 | 2021 | |
| Medtronic, INC. | $153.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $63.20 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $56.62 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $51.81 | 2021-2022 | |
| Amarin Pharma, INC. | $42.16 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $39.35 | 2023-2024 | Quviviq |
| Currax Pharmaceuticals LLC | $31.70 | 2023-2025 | Contrave, Onzetra Xsail |
| Biomarin Pharmaceutical INC. | $22.14 | 2024 | Voxzogo 1.2mg |
| Glaxosmithkline, LLC. | $21.25 | 2023 | Trelegy Ellipta |
| Eisai INC. | $17.83 | 2021 | |
| Agile Therapeutics, INC. | $16.96 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.97 | 2022 | |
| Insulet Corporation | $14.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chey Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.